Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,084 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 4,084 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $93.14, for a total transaction of $380,383.76. Following the completion of the sale, the chief executive officer now owns 226,235 shares of the company’s stock, valued at approximately $21,071,527.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, April 23rd, Steven Leonard Chapman sold 2,552 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76.
• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The stock was sold at an average price of $93.13, for a total transaction of $634,774.08.
• On Thursday, March 28th, Steven Leonard Chapman sold 2,662 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $240,698.04.
• On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
• On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.

Natera Price Performance

NTRA stock opened at $94.15 on Thursday. The firm has a 50 day moving average of $89.57 and a 200 day moving average of $68.74. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $98.82.

Natera (NASDAQ:NTRA) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The company had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Equities analysts predict that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC lifted its stake in Natera by 28.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after acquiring an additional 159,993 shares during the period. Cerity Partners LLC lifted its stake in shares of Natera by 1,043.3% in the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after purchasing an additional 82,514 shares during the period. WCM Investment Management LLC lifted its stake in shares of Natera by 101.2% in the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock valued at $9,058,000 after purchasing an additional 73,419 shares during the period. abrdn plc acquired a new position in shares of Natera in the 4th quarter valued at $3,214,000. Finally, Aigen Investment Management LP acquired a new position in shares of Natera in the 3rd quarter valued at $223,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on NTRA shares. Stephens reissued an “overweight” rating and set a $78.00 target price on shares of Natera in a research report on Tuesday, January 30th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price on the stock in a research report on Friday, April 5th. Piper Sandler raised their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Craig Hallum started coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.40.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.